Alicia J Jenkins1, Dongxu Fu2, Madona Azar3, Julie A Stoner4, Derrick G Kaufman5, Sarah Zhang6, Richard L Klein7, Maria F Lopes-Virella7, Jian-Xing Ma8, Timothy J Lyons9. 1. Centre for Experimental Medicine, Queen's University of Belfast, Belfast, N. Ireland; University of Sydney, NHMRC Clinical Trials Centre, Camperdown, Sydney, NSW, Australia. 2. Centre for Experimental Medicine, Queen's University of Belfast, Belfast, N. Ireland. 3. Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 4. College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 5. Hines VA Cooperative Studies Program (CSP) Coordinating Center, Edward Hines Jr. VA Hospital, Hines, IL, USA. 6. Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Ross Eye Institute, Department of Ophthalmology, State University of New York at Buffalo, Buffalo, NY, USA. 7. Division of Endocrinology, Medical University of South Carolina, Charleston, SC, USA. 8. Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 9. Centre for Experimental Medicine, Queen's University of Belfast, Belfast, N. Ireland; Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: t.lyons@qub.ac.uk.
Abstract
AIM: To determine if serum pigment epithelium-derived factor (PEDF) levels in Type 2 diabetes are related to vascular risk factors and renal function. METHODS: PEDF was quantified by ELISA in a cross-sectional study of 857 male Veterans Affairs Diabetes Trial (VADT) subjects, and associations with cardiovascular risk factors and renal function were determined. In a subset (n=246) in whom serum was obtained early in the VADT (2.0±0.3 years post-randomization), PEDF was related to longitudinal changes in renal function over 3.1 years. RESULTS: Cross-sectional study: In multivariate regression models, PEDF was positively associated with serum triglycerides, waist-to-hip ratio, serum creatinine, use of ACE inhibitors or angiotensin receptor blockers, and use of lipid-lowering agents; it was negatively associated with HDL-C (all p<0.05). Longitudinal study: PEDF was not associated with changes in renal function over 3.1 years (p>0.09). CONCLUSIONS: Serum PEDF in Type 2 diabetic men was cross-sectionally associated with dyslipidemia, body habitus, use of common drugs for blood pressure and dyslipidemia, and indices of renal function; however, PEDF was not associated with renal decline over 3.1years.
AIM: To determine if serum pigment epithelium-derived factor (PEDF) levels in Type 2 diabetes are related to vascular risk factors and renal function. METHODS:PEDF was quantified by ELISA in a cross-sectional study of 857 male Veterans Affairs Diabetes Trial (VADT) subjects, and associations with cardiovascular risk factors and renal function were determined. In a subset (n=246) in whom serum was obtained early in the VADT (2.0±0.3 years post-randomization), PEDF was related to longitudinal changes in renal function over 3.1 years. RESULTS: Cross-sectional study: In multivariate regression models, PEDF was positively associated with serum triglycerides, waist-to-hip ratio, serum creatinine, use of ACE inhibitors or angiotensin receptor blockers, and use of lipid-lowering agents; it was negatively associated with HDL-C (all p<0.05). Longitudinal study: PEDF was not associated with changes in renal function over 3.1 years (p>0.09). CONCLUSIONS: Serum PEDF in Type 2 diabeticmen was cross-sectionally associated with dyslipidemia, body habitus, use of common drugs for blood pressure and dyslipidemia, and indices of renal function; however, PEDF was not associated with renal decline over 3.1years.
Authors: S Famulla; D Lamers; S Hartwig; W Passlack; A Horrighs; A Cramer; S Lehr; H Sell; J Eckel Journal: Int J Obes (Lond) Date: 2010-10-12 Impact factor: 5.095
Authors: William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: Alicia Jenkins; Sarah X Zhang; Albina Gosmanova; Christopher Aston; Azar Dashti; Mary Zoe Baker; Timothy Lyons; Jian-Xing Ma Journal: Diabetes Res Clin Pract Date: 2008-08-19 Impact factor: 5.602
Authors: Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2017-06-08
Authors: LaQueta K Hudson; Meghan E Dancho; Jianhua Li; Johanna B Bruchfeld; Ahmed A Ragab; Mingzhu M He; Meaghan Bragg; Delaney Lenaghan; Michael D Quinn; Jason R Fritz; Matthew V Tanzi; Harold A Silverman; William M Hanes; Yaakov A Levine; Valentin A Pavlov; Peder S Olofsson; Jesse Roth; Yousef Al-Abed; Ulf Andersson; Kevin J Tracey; Sangeeta S Chavan Journal: Mol Med Date: 2016-06-10 Impact factor: 6.354
Authors: April M Teague; David A Fields; Christopher E Aston; Kevin R Short; Timothy J Lyons; Steven D Chernausek Journal: Reprod Biol Endocrinol Date: 2015-06-26 Impact factor: 5.211
Authors: Elaine Hui; Chun-Yip Yeung; Paul C H Lee; Yu-Cho Woo; Carol H Y Fong; Wing-Sun Chow; Aimin Xu; Karen S L Lam Journal: J Clin Endocrinol Metab Date: 2014-08-28 Impact factor: 5.958